CBCaroline Bähler

Caroline Bähler

*This is an algorithmically generated author record based on publicly available information.

Caroline Bähler has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patterns in outpatient antibiotic prescribing in Switzerland: a five-year analysis of claims data from 2019 to 2023

    by Philipp Stefan Aebi, Lena Zwicker, Melinda Toth, Caroline Bähler, Christian Frei, Maria Trottmann, Reto Auer, Adrian Rohrbasser

    Objective: Antimicrobial resistance threatens the effectiveness of future therapies. Interventions to reduce the rate of unnecessary antibiotics prescription in the Swiss outpatient setting typically target primary care physicians (PCPs). However, patients might receive antibiotics from other healthcare providers. We set out to provide a descriptive analysis of total antibiotic prescribing and the providers who prescribed them among patients in such a plan. Methods: We performed a retrospective repeated yearly cross-sectional study from 2019 to 2023 in claims data from one insurer in Switzerland (SWICA insurance). We restricted the sample to patients registered in a managed-care plan with PCP serving as a gatekeeper in the SWICA database. We provide descriptive statistics of total antibiotic prescription fills, the proportion of antibiotics prescribed by the gatekeeping PCP vs other healthcare providers and the type of antibiotic prescribed. Results: The population comprised 106,307 patients in 2019 and 113,343 in 2023. The gatekeeping PCP accounted for 40% of antibiotic prescription in 2019, and 36% in 2023. In 2023, other group practices, other PCPs and hospital outpatient departments together accounted for 40% of prescription fills. Gatekeeping PCPs issued a higher proportion of Watch antibiotics than other providers in both 2019 (35% vs 25%) and 2023 (30% vs 21%). Conclusion: In a restricted sample of patients affiliated in a healthcare plan where PCP serve as gatekeepers in one insurance in Switzerland, most outpatient antibiotics were not prescribed by the primary gatekeeping PCP. Future antibiotic stewardship interventions in outpatients should consider further prescribers in the network.

  • Open Access

    Continuity of care and treatment intensity at the end of life in Swiss cancer patients

    by Caroline Bähler, Markus Näpflin, Martin Scherer, Eva Blozik

    Background: Continuity of care (COC) was shown to be associated with fewer hospitalizations. We aimed to evaluate whether COC was associated with intensive intervention(s) at the end of life (IEOL), a preference-sensitive outcome, in cancer patients. Methods: The study is based on claims data of patients with incident use of anti-neoplastics in Switzerland. COC Index, Usual Provider Continuity score, Sequential Continuity index and Modified Modified Continuity Index were calculated based on consultations with the usual ambulatory care physician. Treatment intensity was evaluated in the last 6 months of life, and COC was evaluated in months 18–6 before death in those who died between 24 and 54 months after incident cancer. IEOL comprised life-sustaining interventions (cardiac catheterization, cardiac assistance device implantation, pulmonary artery wedge monitoring, cardiopulmonary resuscitation/cardiac conversion, gastrostomy, blood transfusion, dialysis, mechanical ventilator utilization and intravenous antibiotics) and measures specifically used in cancer patients (last dose of chemotherapy ≤14 days of death, a new chemotherapy regimen starting 14 days in hospital in the last month of life and death in an acute-care hospital). Results: All COC scores were inversely associated with the occurrence of an IEOL, as were older age, homecare nursing utilization and density of ambulatory care physicians. For COC Index, odds ratio was 0.55 (95% confidence interval 0.37–0.83). Conclusions: COC scores were consistently and inversely related to IEOL. The study supports efforts to improve COC for cancer patients at their end of life.


  • Open Access

    Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study

    by Caroline Bähler, Beat Brüngger, Eva Blozik, Stephan R. Vavricka, Alain M. Schoepfer

    Introduction: Medical care and surveillance of inflammatory bowel disease (IBD) patients have been shown to be far from satisfactory. Data on therapy patterns and surveillance measures in IBD patients are scarce. We, therefore, aimed to compare the therapy patterns and surveillance management of IBD patients in the year before and after IBD-related hospitalization. Methods: We examined medical therapy, surveillance management (influenza vaccination, dermatologist visits, Pap smear screening, creatinine measurements, iron measurements, and ophthalmologist visits) and healthcare utilization in 214 ulcerative colitis (UC) and 259 Crohn’s disease (CD) patients who underwent IBD-related hospitalization from 2012 to 2014. Results: IBD-related drug classes changed in 64.5% of IBD patients following hospitalization. During the 1-year follow-up period, biological treatment increased in UC and CD patients, while steroid use decreased. Following hospitalization, 63.1% of UC and 27.0% of CD patients received 5-ASA. Only 21.6% of all IBD patients had a flu shot, and 19.6% of immunosuppressed IBD patients were seen by a dermatologist in the follow-up; other surveillance measures were more frequent. Surveillance before hospital admission and consultations by gastroenterologists were strongly correlated with surveillance during the postoperative follow-up, while gender and diagnosis (UC vs. CD) were not. During the 1-year follow-up, 20.5% of all IBD patients had no diagnostic or disease-monitoring procedure. Discussion/Conclusion: Surveillance measures for IBD patients are underused in Switzerland. Further research is needed to examine the impact of annual screenings and surveillance on patient outcomes.

  • Open Access

    Surgical procedures in inpatient versus outpatient settings and its potential impact on follow-up costs

    by Beat Brüngger, Caroline Bähler, Matthias Schwenkglenks, Agne Ulyte, Holger Dressel, Viktor von Wyl, Oliver Gruebner, Wenjia Wei, Miquel Serra-Burriel, Eva Blozik


  • Open Access

    Are weak or negative clinical recommendations associated with higher geographical variation in utilisation than strong or positive recommendations? Cross-sectional study of 24 healthcare services

    by Agne Ulyte, Wenjia Wei, Oliver Gruebner, Caroline Bähler, Beat Brüngger, Eva Blozik, Viktor von Wyl, M Schwenkglenks, Holger Dressel

    Objectives When research evidence is lacking, patient and provider preferences, expected to vary geographically, might have a stronger role in clinical decisions. We investigated whether the strength or the direction of recommendation is associated with the degree of geographic variation in utilisation. Design In this cross-sectional study, we selected 24 services following a comprehensive approach. The strength and direction of recommendations were assessed in duplicate. Multilevel models were used to adjust for demographic and clinical characteristics and estimate unwarranted variation. Setting Observational study of claims to mandatory health insurance in Switzerland in 2014. Participants Enrolees eligible for the 24 healthcare services. Primary outcome measures The variances of regional random effects, also expressed as median odds ratios (MOR). Services grouped by strength and direction of recommendations were compared with Welch’s t-test. Results The sizes of the eligible populations ranged from 1992 to 409 960 patients. MOR ranged between 1.13 for aspirin in secondary prevention of myocardial infarction to 1.68 for minor surgical procedures performed in inpatient instead of outpatient settings. Services with weak recommendations had a negligibly higher variance and MOR (difference in means (95% CI) 0.03 (−0.06 to 0.11) and 0.05 (−0.11 to 0.21), respectively) compared with strong recommendations. Services with negative recommendations had a slightly higher variance and MOR (difference in means (95% CI) 0.07 (−0.03 to 0.18) and 0.14 (−0.06 to 0.34), respectively) compared with positive recommendations. Conclusions In this exploratory study, the geographical variation in the utilisation of services associated with strong vs weak and negative vs positive recommendations was not substantially different, although the difference was somewhat larger for negative vs positive recommendations. The relationships between the strength or direction of recommendations and the variation may be indirect or modified by other characteristics of services. As initiatives discouraging low-value care are gaining attention worldwide, these findings may inform future research in this area.


  • Open Access

    Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study

    by Caroline Bähler, Beat Brüngger, Agne Ulyte, Matthias Schwenkglenks, Viktor von Wyl, Holger Dressel, Oliver Gruebner, Wenjia Wei, Eva Blozik

    Background: We examined colorectal, breast, and prostate cancer screening utilization in eligible populations within three data cross-sections, and identified factors potentially modifying cancer screening utilization in Swiss adults. Methods: The study is based on health insurance claims data of the Helsana Group. The Helsana Group is one of the largest health insurers in Switzerland, insuring approximately 15% of the entire Swiss population across all regions and age groups. We assessed proportions of the eligible populations receiving colonoscopy/fecal occult blood testing (FOBT), mammography, or prostate-specific antigen (PSA) testing in the years 2014, 2016, and 2018, and calculated average marginal effects of individual, temporal, regional, insurance-, supply-, and system-related variables on testing utilization using logistic regression. Results: Overall, 8.3% of the eligible population received colonoscopy/FOBT in 2014, 8.9% in 2016, and 9.2% in 2018. In these years, 20.9, 21.2, and 20.4% of the eligible female population received mammography, and 30.5, 31.1, and 31.8% of the eligible male population had PSA testing. Adjusted testing utilization varied little between 2014 and 2018; there was an increasing trend of 0.8% (0.6–1.0%) for colonoscopy/FOBT and of 0.5% (0.2–0.8%) for PSA testing, while mammography use decreased by 1.5% (1.2–1.7%). Generally, testing utilization was higher in French-speaking and Italian-speaking compared to German-speaking region for all screening types. Cantonal programs for breast cancer screening were associated with an increase of 7.1% in mammography utilization. In contrast, a high density of relevant specialist physicians showed null or even negative associations with screening utilization. Conclusions: Variation in cancer screening utilization was modest over time, but considerable between regions. Regional variation was highest for mammography use where recommendations are debated most controversially, and the implementation of programs differed the most.


  • Regional differences in healthcare costs at the end of life: an observational study using Swiss insurance claims data

    by Caroline Bähler, Roland Rapold, Andri Signorell, Oliver Reich, Radoslaw Panczak, Eva Blozik

    Objectives We evaluated healthcare cost differences at the end of life (EOL) between language regions in Switzerland, accounting for a comprehensive set of variables, including treatment intensity. Methods We evaluated 9716 elderly who died in 2014 and were insured at Helsana Group, with data on final cause of death provided by the Swiss Federal Statistical Office. EOL healthcare costs and utilization, ≥ 1 ICU admission and 10 life-sustaining interventions (cardiac catheterization, cardiac assistance device implantation, pulmonary artery wedge monitoring, cardiopulmonary resuscitation, gastrostomy, blood transfusion, dialysis, mechanical ventilation, intravenous antibiotics, cancer chemotherapies) reimbursed by compulsory insurance were examined. Results Taking into consideration numerous variables, relative cost differences decreased from 1.27 (95% CI 1.19–1.34) to 1.06 (CI 1.02–1.11) between the French- and German-speaking regions, and from 1.12 (CI 1.03–1.22) to 1.08 (CI 1.02–1.14) between the Italian- and German-speaking regions, but standardized costs still differed. Contrary to individual factors, density of home-care nurses, treatment intensity, and length of inpatient stay explain a substantial part of these differences. Conclusions Both supply factors and health-service provision at the EOL vary between Swiss language regions and explain a substantial proportion of cost differences.


  • Open Access

    Follow-Up Ileocolonoscopy Is Underused in Crohn’s Disease Patients after Ileocecal Resection despite Higher Total and Inpatient Health-Care Costs Compared to Controls

    by Stephan R. Vavricka, Thomas Greuter, Beat Brüngger, Eva Blozik, Jennifer Celeiro, Alain M. Schoepfer, Caroline Bähler

    Background: Postoperative recurrence is frequently observed after ileocecal resection in Crohn’s disease (CD) patients. Since 2010, endoscopy within 1 year is considered the gold standard for its diagnosis. However, if and how frequent such endoscopies are performed in clinical practice remains unknown. Methods: We analyzed 1-year follow-up data on CD patients who underwent ileocecal resection between 2012 and 2014 and compared them with hospitalized, non-resected CD controls. Data were extracted from the Helsana database. Helsana is one of the largest Swiss health insurance companies providing coverage for 1.2 million individuals. Results: A total of 645 CD patients were identified with ≥1 hospitalization between 2012 and 2014 and a follow-up of 1 year. Of these, 79 (12.2%) underwent ileocecal resection. Although endoscopy rates increased over time and were higher in patients with resection versus controls (p = 0.029), in only 54.4% a 1-year follow-up ileocolonoscopy was performed. Postoperative prophylaxis with anti-tumor necrosis factor or azathioprine was prescribed in 63.3%. Female sex and age >60 years were independent predictors for not receiving prophylaxis (odds ratio [OR] 0.36, p = 0.048, and OR 0.2, p = 0.022). Patients with resection had significantly lower numbers of rehospitalizations (1.2 vs. 1.8, p = 0.021), with resection being an independent negative predictor for number of rehospitalizations in a Poisson regression model (incident risk ratio 0.64, p = 0.029). However, disease-related surgery was more often the cause for rehospitalization after resection versus controls (47.6 vs. 22.1%, p = 0.015). Total and inpatient health-care costs were higher in these patients. Conclusion: Endoscopies are underused after ileocecal resection. This contrasts current guidelines. Physicians should be aware of this underuse and perform follow-up examinations more often.


  • Open Access

    Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis

    by Caroline Baehler, Beat Brüngger, Eva Blozik, Stephan R. Vavricka, Alain M. Schoepfer

    Objectives: Topical treatment with aminosalicylates and/or budesonide was shown to be highly effective in patients with ulcerative colitis (UC), while reducing the likelihood of systemic adverse effects. However, previous research has shown that topical treatment is clearly underused. We aimed to evaluate the use of topical therapy in the real-world setting. Methods: This is an observational study based on claims data of 201 Swiss adult patients who were hospitalized for UC between 2012 and 2014 and who were then followed for 1 year. A variety of factors presumably associated with topical treatment were examined. Annual health care utilization (UC-related medications, diagnostic procedures, consultations, and rehospitalizations) of patients with versus without topical therapy was compared. Results: Of the 201 hospitalized UC patients, 82 (40.8%) were treated with topical 5-acetylsalicylic acid (ASA) and/or topical rectal steroids. The main factors significantly and positively associated with receiving topical treatment were the use of topical treatment in the year prior to the hospitalization, receiving oral 5-ASA, and living in an urban area. The mode of administration was further related to the language area. Patients with topical therapy significantly more often received other UC-related medications, such as combinations with systemic steroids. They significantly more often underwent colonoscopies and calprotectin measurements, and more often consulted a gastroenterologist in the follow-up, while there was no significant difference regarding rehospitalizations. Conclusions: Topical treatment is underused in patients with UC, which stands in contrast to the current European Crohn’s and Colitis Organization guidelines. Patients’ preferences and considerations need to be taken into account when prescribing medical therapy.


  • Open Access

    Medizinische Versorgung von Schweizer Krebspatienten am Lebensende

    by Caroline Bähler, Eva Blozik, Andri Signorell, Oliver Reich